Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
69 studies found for:    Open Studies | "Thalassemia"
Show Display Options
Rank Status Study
21 Recruiting Benefits of Nigella Sativa in Children With Beta Thalassemia Major
Condition: Nigella Sativa With Beta Thalassemia Major
Intervention: Drug: nigella sativ
22 Not yet recruiting Screening for Alpha Thalassemia in Healthy Volunteers
Condition: Alpha Thalassemia
23 Recruiting Unrelated Umbilical Cord Blood Following HLA-haploidentical Hematopoietic Stem Cell Transplantation in Patients With β-thalassemia Major
Condition: Thalassemia Major
Intervention: Genetic: unrelated CB following haplo-identical hematopoietic stem cells transplantation
24 Recruiting Stem Cell Transplant for Patients With Sickle Cell Disease (SCD), Thalassemia, Diamond Blackfan Anemia (DBA) and Other Non-malignant (Non-cancerous) Hematologic Disorders
Conditions: Sickle Cell Disease;   Thalassemia;   Diamond Blackfan Anemia;   Non-malignant Hematologic Disorders
Interventions: Drug: Anti-thymocyte globulin (ATG);   Drug: Fludarabine monophosphate;   Drug: Busulfan;   Drug: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Mesna;   Radiation: total body irradiation
25 Unknown  Genetics of Alpha Thalassemia in Israeli Ethnic Groups
Condition: Alpha Thalassemia
26 Recruiting Dose-Escalation Study of SCD-101 in Sickle Cell Disease
Conditions: Sickle Cell Disease;   Sickle-Beta Zero Thalassemia
Intervention: Drug: SCD-101
27 Unknown  Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Conditions: Sickle Cell Anemia;   Beta-Thalassemia;   Microalbuminuria
Intervention: Other: No intervention
28 Recruiting Therapeutic Effect of Colla Corii Asini on Improving Anemia and Hemoglobin Composition in Pregnant Women With Thalassemia
Condition: Thalassemia
Intervention: Drug: Colla corii asini
29 Unknown  Role of Vitamin C to Augment Iron Chelation With DFP or DFX
Conditions: Vitamin c;   Thalassemia Major;   Iron Chelation
Interventions: Drug: Vitamin C, Defriprone, deferisarox;   Drug: deferiprone , deferesarox
30 Unknown  Therapeutic Effect and Safety of Combined Hydroxyurea With Recombinant Human Erythropoietin.
Condition: Thalassemia Intermedia
Interventions: Drug: Hydroxyurea ,Epiao;   Drug: hydroxyurea, blood transfusion
31 Recruiting B-Thalasaemia Trait and Its Possible Cardioprotective Role
Conditions: Beta-Thalassemia Trait;   Coronary Artery Disease
32 Unknown  Study Of Efficacy,Safety of Combined Deferasirox and Deferiprone Versus Combined Deferiprone and Desferal In Conditions of Iron Overload
Conditions: Beta-thalassemia Major;   Sickle Cell Disease;   Iron Hemosiderosis
Interventions: Drug: DFP (ferriprox) and deferasirox (ICL 670);   Drug: DFP, DFO
33 Recruiting Use of Mobile Technology for Intensive Training in Medication Management
Conditions: Sickle Cell Disease;   Thalassemia
Interventions: Behavioral: Video recording;   Behavioral: Medication Administration Log;   Behavioral: Education
34 Recruiting CD34+ Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation for Non-Malignant Disease
Conditions: Bone Marrow Failure Syndrome;   Severe Aplastic Anemia;   Severe Congenital Neutropenia;   Amegakaryocytic Thrombocytopenia;   Diamond-Blackfan Anemia;   Schwachman Diamond Syndrome;   Primary Immunodeficiency Syndromes;   Acquired Immunodeficiency Syndromes;   Histiocytic Syndrome;   Familial Hemophagocytic Lymphocytosis;   Lymphohistiocytosis;   Macrophage Activation Syndrome;   Langerhans Cell Histiocytosis (LCH);   Hemoglobinopathies;   Sickle Cell Disease;   Sickle Cell-beta-thalassemia
Intervention: Biological: CD34 Stem Cell Selection Therapy
35 Unknown  A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD)
Conditions: Sickle Cell Disease;   HEMOGLOBIN SS;   Hemoglobin S Beta-0 Thalassemia;   Inflammation;   Quality of Life
Interventions: Dietary Supplement: Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA);   Other: Placebo Capsules
36 Recruiting Pilot Study Evaluating Safety & Efficacy of a DCBT: NiCord® & UNM CBU to SCD Patients After Myeloablative Therapy
Condition: Sickle Cell Disease & Thalassemia
Intervention: Drug: NiCord
37 Recruiting BMT Abatacept for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman-Diamond Syndrome;   Diamond-Blackfan Anemia;   Dyskeratosis-congenita;   Chediak-Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia Major;   Hemophagocytic Lymphohistiocytosis;   Sickle Cell Disease
Intervention: Drug: Abatacept
38 Recruiting A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Conditions: Hematologic Malignancies;   Certain:;   Inherited Disorders of Metabolism;   Inherited Abnormalities of Erythrocyte Differentiation or Function;   Inherited Abnormalities of Platelets;   Disorders of the Immune System;   Histiocytic Disorders;   X-linked Lymphoproliferative Syndrome;   Primary Immunodeficiency Diseases;   Bone Marrow Failure;   Beta-thalassemia
Intervention: Drug: A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)
39 Recruiting Effect of Spirulina on Liver Iron Concentration in Beta Thalassemic Children With Hepatitis C
Condition: Beta Thalassemia Major
Intervention: Dietary Supplement: spirulina
40 Recruiting Effect of Spirulina on Serum Hyaluronic Acid in Beta Thalassemic Children With Hepatitis C
Condition: Beta Thalassemia Major
Intervention: Dietary Supplement: Spirulina

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years